uploads/2018/01/ARRY-Analysts-reco-2.png

Analyst Ratings for Array BioPharma and Peers in January 2018

By

Updated

Company overview

Array BioPharma (ARRY) is a biopharmaceutical company focused on discovery, development, and commercialization of small molecule drugs for the treatment of patients suffering from cancer.

The company has undertaken nine trials for its seven proprietary and partnered drugs listed below:

  • binimetinib
  • encorafenib with AstraZeneca
  • selumetinib with AstraZeneca
  • danoprevir
  • ipatasertib with Roche Holding
  • larotrectinib with Loxo Oncology
  • tucatinib with Cascadian Therapeutics
Article continues below advertisement

Analyst ratings

Of the nine analysts covering Array BioPharma (ARRY) in January 2018, eight have given the stock a “buy” or higher rating, and one has given it a “hold.” The mean rating for the stock is 1.78 with a target price of $16.22.

Array BioPharma makes up 1.9% of the SPDR S&P Biotech ETF’s (XBI) total portfolio holdings.

Peer ratings

Of the four analysts covering Novartis (NVS) in January 2018, two analysts have given the stock a “buy” or higher rating. The mean rating for the stock is 2.5 with a target price of $93.

Of the 26 analysts covering Amgen (AMGN) in January 2018, 11 analysts have given the stock a “buy” or higher rating, and 15 have given it a “hold.” The mean rating for the stock is 2.42 with a target price of $192.14.

Of the 24 analysts covering Bristol-Myers Squibb (BMY) in January 2018, ten analysts have given the stock a “buy” or higher rating, 12 have given it a “hold,” and the remaining two have given it a “sell.” The mean rating for the stock is 2.42 with a target price of $64.05.

In the next part of this series, we’ll take a look at Array BioPharma’s pipeline of drugs.

Advertisement

More From Market Realist